22
Feb
2023
11:30
GMT
12:30
CET
06:30
EST
Webinar
Individualising Antithrombotic Strategies for Established Coronary Artery Disease
-
Views:
7828
-
Likes:
31
Overview
Chaired by Prof Marco Valgimigli (Istituto Cardiocentro Ticino, Lugano, CH), this live broadcast will address the importance of providing individualised treatment in Acute Coronary Syndrome (ACS) and Chronic Coronary Syndrome (CCS).
We will start by reviewing the two patient cases presented in phase one of this programme by Prof Eliano Navarese (Nicolaus Copernicus University PL) and Prof Pascal Vranckx (Hartcentrum Hasselt, BE). Our international panel will then discuss best management practice for each case, leveraging data from guidelines and the latest clinical trials to support their approach.
Our expert panel will also review challenges experienced in daily practice whilst offering practical solutions to the audience. In addition, Prof Vijay Kunadian (Newcastle University, UK) will present on individualising antiplatelet therapy in established Coronary Artery Disease (CAD).
This programme is supported by an unrestricted educational grant from AstraZeneca.
This programme has been accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 CME point, equating to 1 hour of learning. Physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™.
Faculty:
Marco Valgimigli
Vijay Kunadian
Pascal Vranckx
Eliano Navarese
This programme is supported by an unrestricted educational grant from AstraZeneca.
Agenda
Learning Objectives
- Summarise current guidance for choosing antithrombotic therapy in established CAD
- Describe current gaps in clinical evidence and what is missing from current guidance
- Adopt an evidence-based approach for managing patients with ACS and CCS
Target Audience
- General Cardiologists
- Interventional Cardiologists
- Nurses
- HCPs
Faculty Biographies
Marco Valgimigli
Prof Marco Valgimigli is an Interventional Cardiologist and Deputy Chief of Cardiology at the Cardiocentro Ticino Institute in Lugano, Switzerland.
He obtained his medical degree from the University of Bologna, and completed his training in internal medicine at the same university. He received a degree in cardiological sciences at the University of Ferrara and a PhD in interventional cardiology at Erasmus Medical Center in Rotterdam.
Prof Valgimigli’s areas of research are wide ranging and include high-risk percutaneous interventions (PCI); invasive treatment of myocardial ischaemia (MI); reparative medicine with adult stem cells during MI and heart failure; antithrombotic therapy during and after PCI; and prognostic stratification during acute coronary syndromes and MI.
Vijay Kunadian
Prof Vijay Kunadian is Personal Chair and Professor of Interventional Cardiology at Newcastle University.
Prof Kunadian completed all her cardiology training in the North East of England. She undertook an international academic fellowship in cardiology at the TIMI/PERFUSE Study group, Brigham and Women’s Hospital/Harvard Medical School, Boston MA.
Prof Kunadian has an international reputation in interventional cardiology and cardiovascular research, making her a sought-after and respected speaker at prominent national and international meetings. She has championed diversity in her specialty as a role model; only 5% of interventional cardiologist are female in the UK, <1% are clinical academics.
Pascal Vranckx
Prof Pascal Vranckx is a Clinical Consultant in Interventional Cardiology and Medical Director of Cardiac Critical Care Services at the Hartcentrum Hasselt in Belgium, and Professor of Medicine at the University of Hasselt, Belgium.
Prof Vranckx is also board member of the European Cardiovascular Research Institute, in Rotterdam, The Netherlands.
Eliano Navarese
Prof Eliano Navarese is an Interventional Cardiologist, Associate Professor and Head of Clinical and Experimental Cardiology at the University of Sassari, Sardinia Island in Italy.
His expertise is in the fields of interventional cardiology, coronary artery disease, antithrombotics, lipid-lowering therapies, cardiovascular pharmacotherapy, clinical trials and evidence-based medicine.